Summary
Elevance Health, Inc. (ELV) has successfully closed a significant notes offering totaling approximately $3.0 billion. This issuance includes four tranches with varying interest rates and maturity dates: $750 million in 4.000% Notes due 2028, $750 million in 4.600% Notes due 2032, $1,000 million in 5.000% Notes due 2036, and $500 million in 5.700% Notes due 2055. The company raised approximately $2,972.7 million in net proceeds after deducting underwriting discounts and expenses. The primary use of these proceeds is to refinance existing debt, specifically repaying or redeeming $400 million of 5.350% senior notes due 2025 and repurchasing $500 million of 4.900% senior notes due 2026. The remaining funds are earmarked for general corporate purposes, including potential acquisitions, further debt reduction, and share repurchases. This strategic refinancing aims to optimize the company's debt structure and financial flexibility.
Key Highlights
- 1Elevance Health closed a $3.0 billion notes offering across four tranches with maturity dates ranging from 2028 to 2055.
- 2Net proceeds of approximately $2,972.7 million were raised from the offering.
- 3The company will use a significant portion of the proceeds to repay $400 million of 5.350% notes due 2025 and repurchase $500 million of 4.900% notes due 2026.
- 4Remaining funds are allocated for general corporate purposes, including acquisitions, debt repayment, and share repurchases.
- 5The offering was conducted under an Underwriting Agreement with BofA Securities, Inc., Deutsche Bank Securities Inc., and Mizuho Securities USA LLC.
- 6The notes are governed by an Indenture dated November 21, 2017, with The Bank of New York Mellon Trust Company, N.A. as trustee.
- 7The company retains the option to redeem the notes under specified conditions prior to their maturity dates, with varying premium structures.